Cargando…
Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies
Hepatitis C virus (HCV) is the major cause of chronic liver disease as well as the major indication for liver transplantation worldwide. Current standard of care is not completely effective, not administrable in grafted patients, and burdened by several side effects. This incomplete effectiveness is...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722892/ https://www.ncbi.nlm.nih.gov/pubmed/23935648 http://dx.doi.org/10.1155/2013/450963 |
_version_ | 1782278240306462720 |
---|---|
author | Sautto, Giuseppe Tarr, Alexander W. Mancini, Nicasio Clementi, Massimo |
author_facet | Sautto, Giuseppe Tarr, Alexander W. Mancini, Nicasio Clementi, Massimo |
author_sort | Sautto, Giuseppe |
collection | PubMed |
description | Hepatitis C virus (HCV) is the major cause of chronic liver disease as well as the major indication for liver transplantation worldwide. Current standard of care is not completely effective, not administrable in grafted patients, and burdened by several side effects. This incomplete effectiveness is mainly due to the high propensity of the virus to continually mutate under the selective pressure exerted by the host immune response as well as currently administered antiviral drugs. The E2 envelope surface glycoprotein of HCV (HCV/E2) is the main target of the host humoral immune response and for this reason one of the major variable viral proteins. However, broadly cross-neutralizing monoclonal antibodies (mAbs) directed against HCV/E2 represent a promising tool for the study of virus-host interplay as well as for the development of effective prophylactic and therapeutic approaches. In the last few years many anti-HCV/E2 mAbs have been evaluated in preclinical and clinical trials as possible candidate antivirals, particularly for administration in pre- and post-transplant settings. In this review we summarize the antigenic and structural characteristics of HCV/E2 determined through the use of anti-HCV/E2 mAbs, which, given the absence of a crystal structure of this glycoprotein, represent currently the best tool available. |
format | Online Article Text |
id | pubmed-3722892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37228922013-08-09 Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies Sautto, Giuseppe Tarr, Alexander W. Mancini, Nicasio Clementi, Massimo Clin Dev Immunol Review Article Hepatitis C virus (HCV) is the major cause of chronic liver disease as well as the major indication for liver transplantation worldwide. Current standard of care is not completely effective, not administrable in grafted patients, and burdened by several side effects. This incomplete effectiveness is mainly due to the high propensity of the virus to continually mutate under the selective pressure exerted by the host immune response as well as currently administered antiviral drugs. The E2 envelope surface glycoprotein of HCV (HCV/E2) is the main target of the host humoral immune response and for this reason one of the major variable viral proteins. However, broadly cross-neutralizing monoclonal antibodies (mAbs) directed against HCV/E2 represent a promising tool for the study of virus-host interplay as well as for the development of effective prophylactic and therapeutic approaches. In the last few years many anti-HCV/E2 mAbs have been evaluated in preclinical and clinical trials as possible candidate antivirals, particularly for administration in pre- and post-transplant settings. In this review we summarize the antigenic and structural characteristics of HCV/E2 determined through the use of anti-HCV/E2 mAbs, which, given the absence of a crystal structure of this glycoprotein, represent currently the best tool available. Hindawi Publishing Corporation 2013 2013-07-09 /pmc/articles/PMC3722892/ /pubmed/23935648 http://dx.doi.org/10.1155/2013/450963 Text en Copyright © 2013 Giuseppe Sautto et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Sautto, Giuseppe Tarr, Alexander W. Mancini, Nicasio Clementi, Massimo Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies |
title | Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies |
title_full | Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies |
title_fullStr | Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies |
title_full_unstemmed | Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies |
title_short | Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies |
title_sort | structural and antigenic definition of hepatitis c virus e2 glycoprotein epitopes targeted by monoclonal antibodies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722892/ https://www.ncbi.nlm.nih.gov/pubmed/23935648 http://dx.doi.org/10.1155/2013/450963 |
work_keys_str_mv | AT sauttogiuseppe structuralandantigenicdefinitionofhepatitiscviruse2glycoproteinepitopestargetedbymonoclonalantibodies AT tarralexanderw structuralandantigenicdefinitionofhepatitiscviruse2glycoproteinepitopestargetedbymonoclonalantibodies AT mancininicasio structuralandantigenicdefinitionofhepatitiscviruse2glycoproteinepitopestargetedbymonoclonalantibodies AT clementimassimo structuralandantigenicdefinitionofhepatitiscviruse2glycoproteinepitopestargetedbymonoclonalantibodies |